Table.

Tubulointerstitial Infiltrating Cells in Immune Checkpoint Inhibitor-induced Acute Tubulointerstitial Nephritis.

No.	Age	Sex	ICIs	PPI	Period between initiation of ICIs and AKI (months)	S-Cr (mg/dL)	Infiltrating cells in the kidney*1							Treatment	Outcome	Ref.
						peak	CD3	CD4	CD8	CD20	CD68	CD163	Others
1	75	Male	Ipi+Nivo	-	1	7.31	NA	++	++	NA	NA	NA	granzyme B+, perforin+, Foxp3+	PSL / MMF	Dead	10
2	75	Male	Ipi+Nivo	-	1.5	7.3	++	++	++	+	NA	NA		PSL	PR	8
3	67	Female	Nivo	+	1.5	4.00	++	++	++	NA	NA	NA		PSL	PR	11
4	52	Female	Pem	+	4	1.64	++	++	+	NA	NA	NA		PSL	PR
5	68	Female	Ipi	+	4	1.83	+	+	+	NA	NA	NA		PSL	CR
6	78	Female	Nivo	+	2	3.14*2	++	++	++	NA	+	NA		PSL	CR	12
7	64	Male	Pem	+	4	4.3*2	++	++	+	NA	++	NA		PSL	PR
8	67	Female	Nivo	+	1	5.0	++	++	++	+	++	NA	CD38++, CD1a+, Foxp3+	PSL	PR	13
9	57	Male	Nivo	+	2	3.48	++	++	+	+	++	++	CD1c+	PSL	CR	Our case

ICI: immune checkpoint inhibitor, Ipi: Ipilimumab, PPI: proton pump inhibitor, NA: not available, AKI: acute kidney injury, Nivo: nivolumab, Pem: pembrolizumab, S-Cr: serum creatinine, PSL: prednisolone or prednisone, MMF: micophenolate mofetil, PR: patial recovery of serum creatinine, CR: normalization of serum creatinine

*¹ The degree of infiltrating cells are expressed as follows, based upon the presented photos in the manuscript:++, strong; ’+mild.

*² At presentation